USPTO Examiner PAGANO ALEXANDER R - Art Unit 1692

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18642608ANTIMICROBIAL ORGANOSILANESApril 2024August 2024Allow410NoNo
18404081MONOALKYL TIN COMPOUNDS WITH LOW POLYALKYL CONTAMINATION, THEIR COMPOSITIONS AND METHODSJanuary 2024February 2025Allow1410NoNo
18390624METHOD FOR PRODUCING AMINO ACID DERIVATIVESDecember 2023December 2024Allow1200NoNo
18243409METHOD FOR PRODUCING AMINO ACID DERIVATIVESSeptember 2023October 2024Allow1300NoNo
18333299COMPOSITION OF CATALYSTS FOR CONVERSION OF ETHANOL TO N-BUTANOL AND HIGHER ALCOHOLSJune 2023June 2025Abandon2401NoNo
18205009HIGH PURITY ALKYL TIN COMPOUNDS AND MANUFACTURING METHODS THEREOFJune 2023June 2025Allow2531YesNo
18201100PROCESS FOR PREPARING ORGANOTIN COMPOUNDSMay 2023March 2025Allow2210NoNo
18196281PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORSMay 2023March 2025Abandon2201NoNo
18143500LOW PRESSURE PROCESS FOR SYNTHESIS OF PT(PF3)4 INVOLVING A SOLUBLE INTERMEDIATE AND STORAGE OF OBTAINED PT(PF3)4May 2023January 2025Allow2110NoNo
18310214COMPOSITION, FILM, DISPLAY DEVICE AND ARTICLE PREPARED THEREFROM, AND METHOD OF PREPARING ARTICLEMay 2023April 2025Allow2311NoNo
18192182ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAMEMarch 2023January 2025Allow2210NoNo
18180056SYNTHESIS AND USE OF PRECURSORS FOR ALD OF MOLYBDENUM OR TUNGSTEN CONTAINING THIN FILMSMarch 2023March 2025Allow2521YesNo
18166218POLYORGANOSILOXANE, POLYORGANOSILOXANE COMPOSITION, CURED PRODUCT, POLYORGANOSILOXANE-CONTAINING ELECTROLYTIC SOLUTION FOR ELECTROLYTIC CAPACITOR, AND ELECTROLYTIC CAPACITOR USING SAMEFebruary 2023June 2025Allow2811YesNo
18165870IODINE-CONTAINING METAL COMPOUND AND COMPOSITION FOR DEPOSITING THIN FILM INCLUDING THE SAMEFebruary 2023June 2025Allow2821NoNo
18085157Synthesis of Spermidine, Spermine, and Free Bases ThereofDecember 2022December 2024Abandon2321NoNo
18065572GOLD NANOPARTICLE SUPERLATTICE EMBEDDED IN POROUS SILICA AND METHOD FOR MANUFACTURING SAMEDecember 2022November 2024Allow2301NoNo
18060291PHOTOCHROMIC GERMOLE-FUSED DIARYLETHENES AND PRODUCTION THEREOFNovember 2022July 2024Allow2010NoNo
17928292Complex Containing Betaine, Transition Metal and SulfateNovember 2022May 2025Allow3010NoNo
17981433ORGANOMETALLIC TIN COMPOUNDS AS EUV PHOTORESISTNovember 2022November 2024Allow2410NoNo
17901569VAPOR DEPOSITION PRECURSOR COMPOUNDS AND PROCESS OF USESeptember 2022November 2024Allow2611NoNo
17873746MULTIMETAL-METAL ORGANIC FRAMEWORK ADSORBENTJuly 2022April 2025Allow3211NoNo
17849347AQUEOUS SOLUTION COMPOSITION CONTAINING ORGANOSILICON COMPOUNDJune 2022March 2025Abandon3320NoNo
17843021PROCESS FOR PREPARING ORGANOTIN COMPOUNDSJune 2022December 2024Abandon3021NoNo
17841150TWO-DIMENSIONAL COORDINATION POLYMERSJune 2022January 2025Allow3110NoNo
17731729SUBSTRATE SURFACE MODIFIER FOR ATOMIC LAYER DEPOSITION AND METHOD FOR MODIFYING SURFACE OF SUBSTRATE USING THE SAMEApril 2022May 2025Abandon3621NoNo
17708673P-DIPHENYL COMPOUND DERIVATIVE MIXTURE AND METHOD OF PRODUCING THE SAMEMarch 2022May 2025Abandon3741YesNo
17696019ORGANIC COMPOUND, LIGHT-EMITTING DEVICE, LIGHT-EMITTING APPARATUS, ELECTRONIC DEVICE, AND LIGHTING DEVICEMarch 2022September 2024Allow3040NoNo
17692998Metal Complexes Containing Cyclopentadienyl LigandsMarch 2022February 2025Allow3520YesNo
17591007PROCESS FOR PREPARING ORGANOTIN COMPOUNDSFebruary 2022January 2025Allow3520NoNo
17620900METHOD FOR THE PURIFICATION OF ANILINEDecember 2021May 2025Abandon4121YesNo
17644211RADIOTHERAPY IMPROVEMENTSDecember 2021March 2025Abandon3910NoNo
17512722GROWTH INHIBITOR FOR FORMING THIN FILM, METHOD FOR FORMING THIN FILM AND SEMICONDUCTOR SUBSTRATE PREPARED THEREFROMOctober 2021September 2024Abandon3521NoNo
17594282LUMINESCENT SILAFLUORENE AND GERMAFLUORENE COMPOUNDSOctober 2021June 2025Allow4411NoNo
17598762METHODS FOR SYNTHESIZING BETA-HOMOAMINO ACIDSSeptember 2021February 2025Abandon4010NoNo
17478283HYDROGENATION CATALYSTSeptember 2021March 2025Abandon4221NoNo
174646302D ORGANIC-INORGANIC HYBRID PEROVSKITES AND USES THEREOFSeptember 2021August 2024Allow3621NoNo
17427200FLUORESCENT GTP ANALOGUES AND USEJuly 2021April 2025Allow4521NoNo
17380475ORGANOTIN CLUSTERS, SOLUTIONS OF ORGANOTIN CLUSTERS, AND APPLICATION TO HIGH RESOLUTION PATTERNINGJuly 2021June 2024Allow3431NoNo
17365924Organic Color Center-Tailored, Semiconducting Carbon Nanotubes and Their Method of ManufactureJuly 2021February 2025Allow4441NoNo
17351648Process For Producing Metal Organic FrameworksJune 2021May 2025Allow4711NoNo
17304201NOVEL PRODRUG SALTSJune 2021September 2024Allow3910NoNo
17342077COMPOSITIONS AND METHODS FOR DETERMINING THE PRESENCE OF ACTIVE LEUKOCYTE CELLS USING AN ELECTROCHEMICAL ASSAYJune 2021May 2025Abandon4811NoNo
17291873CATIONIC LIPIDS CONTAINING SILICONMay 2021April 2025Allow4711NoNo
17239991CHIRAL N-SUBSTITUTED ALLYLIC AMINE COMPOUNDSApril 2021May 2024Allow3631NoNo
17258890PROCESS FOR THE PREPARATION OF 2,2',2''-(10-((2R,3S)-1,3,4-TRIHYDROXY BUTAN-2-YL)-1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIYL) TRIACETIC ACID AND ITS COMPLEXESJanuary 2021October 2024Allow4551NoNo
17051970PRODUCTION METHOD FOR ORGANIC SILICON COMPOUND HAVING KETIMINE STRUCTUREOctober 2020November 2024Allow4920NoNo
17051209USE OF N-CHELATING RUTHENIUM COMPLEXES IN THE METATHESIS REACTIONOctober 2020December 2024Allow5020NoNo
17049710ROTAXANE COMPOUNDOctober 2020January 2025Allow5021YesNo
17048372ORGANIC SILICON COMPOUND AND PRODUCTION METHOD THEREFOROctober 2020October 2024Allow4811NoNo
17027113ORGANIC ELECTROLUMINESCENCE DEVICE AND POLYCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICESeptember 2020July 2024Allow4631NoNo
16996543ORGANIC LIGHT-EMITTING DEVICE AND APPARATUS INCLUDING THE SAMEAugust 2020July 2024Allow4731YesNo
16933458ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICESJuly 2020October 2024Allow5140YesNo
16919291MATERIAL FOR HOLE-TRANSPORT LAYER, MATERIAL FOR HOLE-INJECTION LAYER, ORGANIC COMPOUND, LIGHT-EMITTING DEVICE, LIGHT-EMITTING APPARATUS, ELECTRONIC DEVICE, AND LIGHTING DEVICEJuly 2020May 2025Allow5881NoNo
16838353ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE INCLUDING THE SAMEApril 2020February 2025Allow5960NoNo
16651386HALOGENATED HETEROALKENYL- AND HETEROALKYL-FUNCTIONALIZED ORGANIC COMPOUNDS AND METHODS FOR PREPARING SUCH COMPOUNDSMarch 2020March 2025Abandon5941YesNo
16734415GROWTH INHIBITOR FOR FORMING THIN FILM, METHOD FOR FORMING THIN FILM AND SEMICONDUCTOR SUBSTRATE PREPARED THEREFROMJanuary 2020September 2024Abandon5671NoNo
16665815Enhanced Perovskite Materials for Photovoltaic DevicesOctober 2019October 2024Allow6061NoNo
16529213INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTAAugust 2019January 2020Allow600NoNo
16510198PYRIMIDINE-THIAZOLIDINONE DERIVATIVESJuly 2019January 2020Allow700YesNo
16270108ORGANIC ELECTROLUMINESCENCE DEVICE AND POLYCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICEFebruary 2019March 2025Allow6081YesNo
16210492HEPATITIS B ANTIVIRAL AGENTSDecember 2018March 2020Allow1520NoYes
16204166HEPATITIS B ANTIVIRAL AGENTSNovember 2018February 2020Allow1521NoYes
16151597COMPOUNDS OF PHOSPHINANES AND AZAPHOSPHINANES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEMOctober 2018January 2020Allow1620NoNo
15557717METHOD FOR SYNTHESIZING NOVEL COMPOUNDS DERIVED FROM 3-HYDROXY-CYCLOPENTYL ACETIC ACIDSeptember 2017February 2020Allow2921NoNo
15034797AN IMPROVED PROCESS FOR THE PREPARATION OF PAZOPANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOFMay 2016March 2020Allow4751NoNo
14695245Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase InhibitorsApril 2015November 2015Allow700NoNo
14573370INTERMEDIATES TO PREPARE HERBICIDAL PYRIMIDONE DERIVATIVESDecember 2014March 2015Allow300NoNo
14406264MULTICOMPONENT CRYSTALS COMPRISING IMATINIB MESILATE AND SELECTED CO-CRYSTAL FORMERSDecember 2014August 2015Allow800NoNo
14401941TrkA Kinase Inhibitors, Compositions and Methods ThereofNovember 2014July 2015Allow820YesNo
14495337(2-HETEROARYLAMINO) SUCCINIC ACID DERIVATIVESSeptember 2014August 2015Allow1101NoNo
14377951AROMATIC RING COMPOUNDAugust 2014July 2015Allow1201NoNo
14375240Fungicidal Pyrimidine CompoundsJuly 2014February 2015Allow700NoNo
14375238Fungicidal Pyrimidine CompoundsJuly 2014February 2015Allow600NoNo
14262915Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase InhibitorsApril 2014January 2015Allow800NoNo
14238272SUBSTITUTED HETEROCYCLIC AMINE COMPOUNDS AS CHOLESTRYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORSApril 2014July 2015Allow1711NoNo
14113214FLUOROALKYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOFDecember 2013April 2015Allow1711NoNo
14071953CERTAIN PROTEIN KINASE INHIBITORSNovember 2013July 2015Allow2121NoNo
14051464SUBSTITUTED (S)-(2R,3R,5R)-3-HYDROXY-(5-PYRIMIDIN-1-YL)TETRAHYDROFURAN-2-YLMETHYL ARYL PHOSPHORAMIDATEOctober 2013June 2014Allow810NoNo
14047815NOVEL FLUOROERGOLINE ANALOGSOctober 2013July 2014Allow900NoNo
14000261GLYCINE TRANSPORTER-INHIBITING SUBSTANCESAugust 2013April 2014Allow810YesNo
139612185-CYANO-4- (PYRROLO [2,3B] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORSAugust 2013June 2014Allow1000YesNo
13918048INHIBITORS OF INFLUENZA VIRUSES REPLICATIONJune 2013February 2014Allow801NoNo
13991953PYRIMIDINONE AND PYRIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2June 2013June 2014Allow1211NoNo
13824552NOVEL GPR 119 AGONISTSJune 2013April 2014Allow1310NoNo
13905515Cyclothiocarbamate Derivatives as Progesterone Receptor ModulatorsMay 2013May 2014Allow1200YesNo
137025606-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERSMay 2013May 2014Allow1700NoNo
13989602NOVEL POLYMORPH OF NILOTINIB HYDROCHLORIDEMay 2013October 2013Allow500NoNo
13884698HETEROCYCLIC COMPOUNDS AND THEIR USESMay 2013April 2014Allow1111YesNo
13704980RING-FUSED 4-AMINOPYRIMIDINES AND USE THEREOF AS STIMULATORS OF SOLUABLE GUANYLATE CYCLASESFebruary 2013November 2013Allow1100NoNo
13773052HETEROARYL COMPOUNDS AND THEIR USESFebruary 2013March 2014Allow1201NoNo
13679055Cyclothiocarbamate Derivatives as Progesterone Receptor ModulatorsNovember 2012February 2013Allow300YesNo
136750071-PYRIDAZINYL-HYDROXYIMINO-3-PHENYL-PROPANESNovember 2012April 2015Allow2921NoNo
13576296INTERMEDIATES FOR THE PREPARATION OF HMG COA REDUCTASE INHIBITORS AND PROCESSES FOR THE PREPARATION THEREOFOctober 2012March 2014Allow1901YesNo
13515782PROCESSES FOR THE PREPARATION OF KEY INTERMEDIATE FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOFSeptember 2012January 2015Allow3121YesNo
13593776SERINE/THREONINE KINASE INHIBITORSAugust 2012November 2013Allow1501NoNo
13590955CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIESAugust 2012March 2013Allow700NoNo
13531416NOVEL ISO-ERGOLINE DERIVATIVESJune 2012September 2013Allow1400YesNo
13501418INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHRMay 2012March 2014Allow2311NoNo
13496799Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase InhibitorsApril 2012January 2014Allow2211NoNo
13143943PROCESS FOR THE PREPARATION OF ROSUVASTATIN SALTSNovember 2011April 2013Allow2101NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PAGANO, ALEXANDER R.

Strategic Value of Filing an Appeal

Total Appeal Filings
5
Allowed After Appeal Filing
5
(100.0%)
Not Allowed After Appeal Filing
0
(0.0%)
Filing Benefit Percentile
95.6%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner PAGANO, ALEXANDER R - Prosecution Strategy Guide

Executive Summary

Examiner PAGANO, ALEXANDER R works in Art Unit 1692 and has examined 140 patent applications in our dataset. With an allowance rate of 88.6%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 29 months.

Allowance Patterns

Examiner PAGANO, ALEXANDER R's allowance rate of 88.6% places them in the 66% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.

Office Action Patterns

On average, applications examined by PAGANO, ALEXANDER R receive 1.59 office actions before reaching final disposition. This places the examiner in the 42% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by PAGANO, ALEXANDER R is 29 months. This places the examiner in the 44% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a -0.9% benefit to allowance rate for applications examined by PAGANO, ALEXANDER R. This interview benefit is in the 8% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 23.6% of applications are subsequently allowed. This success rate is in the 23% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 54.5% of cases where such amendments are filed. This entry rate is in the 76% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 80.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 50.0% are granted (fully or in part). This grant rate is in the 59% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 2.9% of allowed cases (in the 82% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.